Search Patents
  • COMPOSITIONS INCLUDING CANNABINOID AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATION IN A SUBJECT
    Publication number: 20230398135
    Abstract: Compositions including cannabinoid and use thereof are provided in the present disclosure. In some embodiments, the composition may include cannabidiol (CBD), cannabigerol (CBG), and bakuchiol (BAK). A molar concentration ratio of CBD, CBG, and BAK may be 1:1:1 in the composition. A molar concentration of CBD in the composition may be in a range of 1.67 ?M to 16.7 ?M.
    Type: Application
    Filed: April 21, 2023
    Publication date: December 14, 2023
    Applicant: ANGROW COMPANY LIMITED
    Inventors: Dengfeng YANG, Chunfeng CHAI, Xuan TAN
  • Oral care composition comprising cannabinoids
    Patent number: 10172786
    Abstract: This application discloses oral care compositions comprising cannabinoids, preferably cannabidiol and/or cannabigerol. The oral care composition disclosed in this application may be a tooth paste, a tooth powder, or a mouthwash solution. The oral care composition may be used to treat oral infectious disease, including periimplantitis, periodontitis, oral mucositis, and dental pain.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: January 8, 2019
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George Anastassov, Lekhram Changoer
  • Medicinal cannabis added in food
    Publication number: 20120046351
    Abstract: The invention is a product and a process wherein cannabinoids such as Medicinal ?9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are added to a foodstuff where the medicinal cannabis is not evenly distributed throughout the foodstuff where the food stuff contains a known weight of medicinal cannabis. Another provision of the invention is providing controlled amounts or ratios of ?9-THC as compared to CBD in or on a foodstuff.
    Type: Application
    Filed: August 19, 2011
    Publication date: February 23, 2012
    Inventor: Andrew David Hospodor
  • CANNABIGEROL DERIVATIVES AND USE THEREOF AS CANNABINOID RECEPTOR MODULATORS
    Publication number: 20230150927
    Abstract: The synthesis of a range of pentylbezene-1,3-diol compounds of formula I is disclosed. These compounds bind to cannabinoid 1 and 2 receptors (CB1 and CB2), and are thus presumed to be useful in modulating the activity of such receptors. Accordingly, the use of such synthetic cannabinoids in the treatment of various disorders mediated by CB1 and CB2 is contemplated.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 18, 2023
    Inventors: SIAWASH AHMAR, KRISHNA KUMAR GNANASEKARAN, JEFFREY ALAN OMEARA
  • ALLEVIATION OF ITCHING SENSATIONS USING CANNABINOID COMPOUNDS
    Publication number: 20230000936
    Abstract: Methods of treating itching with cannabinoid compounds are described herein. The cannabinoid compounds can include one or more of cannabidol (“CBD”), cannabichromene (“CBC”), cannabigerol (“CBG”), cannabinol (“CBN”), cannabicyclol (“CBL”), cannabidivarin (“CBDV”), cannabigerivarin (“CBGV”), and cannabicyclolic acid (“CBLA”) and variants thereof. The cannabinoid compounds can be antagonists to the receptors CHRM2, EDG3, and MRGPRX2. Compositions and articles including the cannabinoid compounds are further disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 5, 2023
    Inventors: Cynthia W. Bryant, Alison Watta
  • Psilocybin and/or psilocin in combination with cannabinoids and/or terpenes
    Patent number: 10729706
    Abstract: One or more cannabinoids and/or terpenes in combination with psilocybin and/or psilocin may be used in the prevention or treatment of psychological or brain disorders. The one or more cannabinoids may be taken from the group of cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA).
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 4, 2020
    Assignee: Procare Beheer B.V.
    Inventors: Murat Küçüksen, Ali Neset Küçüksen
  • MEDICINAL ACIDIC CANNABINOIDS
    Publication number: 20070032544
    Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
    Type: Application
    Filed: August 2, 2006
    Publication date: February 8, 2007
    Applicant: Nederlandse Organisatie voor Toegepastnatuurwetenschappelijk Onderzoek TNO
    Inventors: Henricus Korthout, Kitty Verhoeckx, Rentje Witkamp, Robert Doornbos, Mei Wang
  • Acetylation of cannabigerol
    Publication number: 20200398183
    Abstract: A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in cannabis oil reacts with acetic anhydride under reflux to produce THC-O-acetate and acetic acid. The resulting crude product is distilled and subjected to a SALLE with hexane followed by a SALLE with petroleum ether, before being distilled again in order to obtain a refined, THC-O-acetate product.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Inventors: Krupal Devendra Pal, Ryan Delmoral Ko, Brock Aston Hughes, Ivan Jason Casselman
  • Non-Psychoactive Multi-Cannabinoid And Terpene-Based Therapeutic Compositions And Methods Of Their Administration
    Publication number: 20240148759
    Abstract: A fixed dose combination formulation drug comprised of three cannabinoids, namely cannabidiol, cannabichromene, and cannabigerol, and of three terpenes, namely alpha-terpinene, bisabolol, and camphene, in an orally available pharmaceutical carrier, for the alleviation of the adverse effects of cancer chemotherapy agents, including adverse effects on the gastrointestinal tract, the chemoreceptor trigger zone, and the peripheral nervous system, and that shows activity adjunctively against ovarian cancer, particularly ovarian cancer that is therapeutically platinum-resistant or platinum-sensitive.
    Type: Application
    Filed: August 3, 2022
    Publication date: May 9, 2024
    Inventor: Patrick Moran
  • MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT
    Publication number: 20210290564
    Abstract: Disclosed in certain embodiments is a composition for treating nausea and/or vomiting. The composition could be chewable or any other composition suitable for oral administration. The composition may include at least one cannabinoid components, such as cannabidiol and/or cannabigerol, and a ginger component(s). The composition may include any one of these components or any combination of these components in an effective amount to treat nausea and/or vomiting. Also disclosed herein are methods of preparing a composition to treat nausea and/or vomiting and methods of treating nausea and/or vomiting.
    Type: Application
    Filed: March 17, 2021
    Publication date: September 23, 2021
    Inventor: Seth Marcus Shaw
  • ENDOCANNABINOID SYSTEM-TARGETING PRODRUGS AND THERAPEUTIC USES THEREOF
    Publication number: 20220339150
    Abstract: The present invention relates to the process and therapeutic use of endocannabinoid-targeting novel prodrugs in a delivery system. In particular, the present invention relates to prodrugs of endocannabinoid system-targeting molecules, as cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabinol (THC), and cannabichromene (CBC) for oral, transmucosal, transdermal, and parenteral administration, and methods and using the same as therapeutics.
    Type: Application
    Filed: April 7, 2022
    Publication date: October 27, 2022
    Inventors: Tapio NEVALAINEN, Rakshit D. KODEKALRA, Jarkko RAUTIO, Mahadev PATIL, Safwat M. RABEA, David Earl BOGUCKI, Nihar R. PANDEY
  • Method for purifying cannabinoid compounds
    Patent number: 10647691
    Abstract: The present invention relates to methods for purifying one or two cannabinoid compounds using simulated moving bed chromatography, wherein the cannabinoid compound(s) is/are obtained in the extract and/or the raffinate with the total amount of isomeric impurities being below detection level. In particular, the present invention relates to methods for the purification of cannabidiol, trans-(?)-delta-9-tetrahydrocannabinol, cannabidivarin, trans-(?)-delta-9-tetrahydrocannabivarin and cannabigerol which have been obtained by enantiopure synthesis.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: May 12, 2020
    Assignee: SYMRISE AG
    Inventors: Harry Erfurt, Maria Weber, Hans-Jürgen Niemeyer, Marcus Rudolf Götz, Matthias Winkler
  • METHOD FOR PURIFYING CANNABINOID COMPOUNDS
    Publication number: 20190144414
    Abstract: The present invention relates to methods for purifying one or two cannabinoid compounds using simulated moving bed chromatography, wherein the cannabinoid compound(s) is/are obtained in the extract and/or the raffmate with the total amount of isomeric impurities being below detection level. In particular, the present invention relates to methods for the purification of cannabidiol, trans-(?)-delta-9-tetrahydrocannabinol, cannabidivarin, trans-(?)-delta-9-tetrahydrocannabivarin and cannabigerol which have been obtained by enantiopure synthesis.
    Type: Application
    Filed: May 13, 2016
    Publication date: May 16, 2019
    Inventors: Harry ERFURT, Maria WEBER, Hans-Jürgen NIEMEYER, Marcus Rudolf GÖTZ, Matthias WINKLER
  • NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT
    Publication number: 20220296561
    Abstract: Disclosed in certain embodiments is a composition for treating nausea and/or vomiting. The composition could be in any form suitable for non-oral administration. The composition may include at least one cannabinoid components, such as cannabidiol and/or cannabigerol, and a ginger component. The composition may include any one of these components or any combination of these components in an effective amount to treat nausea and/or vomiting. Also disclosed herein are methods of preparing a composition to treat nausea and/or vomiting and methods of treating nausea and/or vomiting.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 22, 2022
    Inventor: Seth Marcus Shaw
  • USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY SKIN DISEASES
    Publication number: 20180263952
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: GW Pharma Limited
    Inventors: Tamás Bíró, Colin Stott, Vincenzo Di Marzo
  • Medicinal Acidic Cannabinoids
    Publication number: 20110021617
    Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
    Type: Application
    Filed: August 25, 2010
    Publication date: January 27, 2011
    Applicant: Nederlandse Organisatie voor Toegepast- Natuurwetenschappelijk Onderzoek TNO
    Inventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
  • Acetylation of cannabigerol
    Patent number: 11097204
    Abstract: A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in cannabis oil reacts with acetic anhydride under reflux to produce THC-O-acetate and acetic acid. The resulting crude product is distilled and subjected to a SALLE with hexane followed by a SALLE with petroleum ether, before being distilled again in order to obtain a refined, THC-O-acetate product.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 24, 2021
    Assignee: Nextleaf Solutions Ltd.
    Inventors: Krupal Devendra Pal, Ryan Delmoral Ko, Brock Aston Hughes, Ivan Jason Casselman
  • Use of cannabinoids in the treatment of inflammatory skin diseases
    Patent number: 11413266
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 16, 2022
    Assignee: GW Pharma Limited
    Inventors: Tamás Biró, Colin Stott, Vincenzo Di Marzo
  • THE OLEO GEL COMPOSITION AND DELIVERY SYSTEM WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND MENTHA ARVENSIS FOR REDUCTION OF INFLAMMATION AND PAIN IN DEEP TISSUES
    Publication number: 20190167749
    Abstract: Disclosed is an oleo gel composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin and Cannabigerol in combination with extract of Olive europaea Fruit Oil, Mentha arvensis leaf oil, and Silica colloidal anhydrous ensuring the delivery of cannabinoids to the deep tissues in order to reduce pain and inflammation of skeletal muscles and joints caused by trauma or/and induced by arthritis/osteoarthritis.
    Type: Application
    Filed: April 7, 2017
    Publication date: June 6, 2019
    Inventor: Juozas SIURKUS
  • plant named ‘PAN2020’
    Patent number: PP32725
    Abstract: A new and distinct variety of Cannabis sativa (L.), named ‘PAN2020’ is characterized by its unique cannabinoid profile, specifically with respect to its high cannabigerol (CBG) content and lack of tetrahydrocannabinol (THC) and cannabidiol (CBD). The new variety resulted from the cross breeding of two Cannabis sativa (L.) clones performed by the inventor and has been asexually reproduced to ensure the resulting clones exhibit the same features and properties as the parent.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 5, 2021
    Assignee: BIOMAX SEEDS S.L.
    Inventors: Ernesto Rafael Llosá Llácer, Salvador Soler Aleixandre
Narrow Results

Filter by US Classification